These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38958145)

  • 41. Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program.
    Labrousse P; Chien YH; Pomponio RJ; Keutzer J; Lee NC; Akmaev VR; Scholl T; Hwu WL
    Mol Genet Metab; 2010 Apr; 99(4):379-83. PubMed ID: 20080426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.
    Schoser BG; Müller-Höcker J; Horvath R; Gempel K; Pongratz D; Lochmüller H; Müller-Felber W
    Neuropathol Appl Neurobiol; 2007 Oct; 33(5):544-59. PubMed ID: 17573812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
    Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS;
    Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
    Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype.
    Morales A; Poling MI; Páez MT; Cabrera J; McCormick RJ
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26160551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship.
    Sampaolo S; Esposito T; Farina O; Formicola D; Diodato D; Gianfrancesco F; Cipullo F; Cremone G; Cirillo M; Del Viscovo L; Toscano A; Angelini C; Di Iorio G
    Orphanet J Rare Dis; 2013 Oct; 8():159. PubMed ID: 24107549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
    Tocan V; Mushimoto Y; Kojima-Ishii K; Matsuda A; Toda N; Toyomura D; Hirata Y; Sanefuji M; Sawada T; Sakai Y; Nakamura K; Ohga S
    Pediatr Int; 2022 Jan; 64(1):e15286. PubMed ID: 36074069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.
    Bali DS; Tolun AA; Goldstein JL; Dai J; Kishnani PS
    Muscle Nerve; 2011 May; 43(5):665-70. PubMed ID: 21484825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
    Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
    Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II.
    McCready ME; Carson NL; Chakraborty P; Clarke JT; Callahan JW; Skomorowski MA; Chan AK; Bamforth F; Casey R; Rupar CA; Geraghty MT
    Mol Genet Metab; 2007 Dec; 92(4):325-35. PubMed ID: 17723315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients.
    Palermo AT; Palmer RE; So KS; Oba-Shinjo SM; Zhang M; Richards B; Madhiwalla ST; Finn PF; Hasegawa A; Ciociola KM; Pescatori M; McVie-Wylie AJ; Mattaliano RJ; Madden SL; Marie SK; Klinger KW; Pomponio RJ
    Mol Genet Metab; 2012 Jul; 106(3):287-300. PubMed ID: 22658377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First clinical and genetic description of a family diagnosed with late-onset Pompe disease from Costa Rica.
    Torrealba-Acosta G; Rodríguez-Roblero MC; Bogantes-Ledezma S; Carazo-Céspedes K; Desnuelle C
    Neuromuscul Disord; 2017 Oct; 27(10):951-955. PubMed ID: 28694071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Broad variation in phenotypes for common GAA genotypes in Pompe disease.
    Niño MY; In't Groen SLM; de Faria DOS; Hoogeveen-Westerveld M; van den Hout HJMP; van der Ploeg AT; Bergsma AJ; Pijnappel WWMP
    Hum Mutat; 2021 Nov; 42(11):1461-1472. PubMed ID: 34405923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Late onset Pompe Disease in India - Beyond the Caucasian phenotype.
    Puri RD; Setia N; N V; Jagadeesh S; Nampoothiri S; Gupta N; Muranjan M; Bhat M; Girisha KM; Kabra M; Verma J; Thomas DC; Biji I; Raja J; Makkar R; Verma IC; Kishnani PS
    Neuromuscul Disord; 2021 May; 31(5):431-441. PubMed ID: 33741225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current status of newborn screening for Pompe disease in Japan.
    Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
    Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
    van Capelle CI; van der Meijden JC; van den Hout JM; Jaeken J; Baethmann M; Voit T; Kroos MA; Derks TG; Rubio-Gozalbo ME; Willemsen MA; Lachmann RH; Mengel E; Michelakakis H; de Jongste JC; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2016 May; 11(1):65. PubMed ID: 27189384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment.
    Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM
    Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease.
    Gharesouran J; Jalaiei A; Hosseinzadeh A; Ghafouri-Fard S; Mokhtari Z; Ghahremanzadeh K; Rezazadeh N; Shiva S; Sadeghvand S; Taheri M; Rezazadeh M
    Metab Brain Dis; 2020 Oct; 35(7):1127-1134. PubMed ID: 32504392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.